Table 2

Characteristics of surgical procedures of vitrectomy alone versus vitrectomy with intravitreal bevacizumab pretreatment included in the meta-analysis

Trials (first author, year)Type of PDRDosage of intravitreal bevacizumabTime prior to pars plana vitrectomyType of pars plana vitrectomyPanretinal photocoagulationGas injectionSilicone oil injectionLens extractSurgeon
Yeh 20091Active severe PDR: visible large new vessels within the proliferative tissue with fresh preretinal and/or VH1.25 mg (0.05 ml)7–9 daysPPVDone

  • 1–: 0

  • 2–: 1

  • 1–: 20

  • 2–: 19

  • 1–: 5

  • 2–: 4

Same
da R Lucena 20092Severe PDR: macula—involving (TRD)1.5 mg (0.06 ml)2 weeks23-gauge PPVNR

  • 1–: 5

  • 2–: 5

  • 1–: 5

  • 2–: 5

  • 1–: 5

  • 2–: 6

Same
Rizzo 20083Severe PDR: TRD, tractional-rhegmatogenous RD, or TRD complicated with VH1.25 mg (0.05 ml)5–7 days20-gauge PPVAll done

  • 1–: 11

  • 2–: 11

00NR
Modarres 20094Complications of PDR2.5 mg (0.1 ml)3–5 days20-gauge PPVDoneNR

  • 1–: 7

  • 2–: 10

NR4
Ahmadieh 20095Complications of PDR: non-clearing VH, TRD involving or threatening the macula, and active progressive PDR1.25 mg (0.05 ml)1 weekStandard PPVNR

  • 1–: 4

  • 2–: 2

  • 1–: 7

  • 2–: 6

NRNR
Yang 20086Active PDR1.25 mg (0.05 ml)7–9 daysStandard PPVDone

  • 1–: 24

  • 2–: 16

0

  • 1–: 4

  • 2–: 2

Same
di Lauro 20109Active PDR: VH and TRD1.25 mg (0.05 ml)7 or 20 days20-gauge PPVDoneNR

  • 1–: 19

  • 2–: 2

NRSame

  • 1–, vitrectomy alone group; 2–, vitrectomy with intravitreal bevacizumab pretreatment; NR, not reported; PDR, proliferative diabetic retinopathy; RD, retinal detachment; TRD, tractional retinal detachment; VH, vitreous haemorrhage.